CareLit · DOI-Nachweis · Nuklearmedizin - NuclearMedicine
Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma
DOI 10.1055/a-0914-2486
Bibliografische Angaben
Nachweis in CareLit
Autor:innenMichael Jüptner, Marlies Marx, Maaz Zuhayra
ZeitschriftNuklearmedizin - NuclearMedicine
Ausgabe04/2019
Jahrgang / SeitenJg. 58 · S. 328-330
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction Systemic radionuclide therapy with 177Lu-PSMA-617 is a novel treatment option in patients with metastasized and castration-resistant prostate cancer 4. The molecular target of the 177Lu-PSMA-617 radioligand therapy is the prostate-specific membrane antigen (PSMA) highly expressed on prostate cancer cells. Beyond the enhanced accumulation of PSMA on prostate cancer cells, PSMA expression is also found o…
Zitieren
Zitierempfehlung
Michael Jüptner, Marlies Marx, Maaz Zuhayra (2019) Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma. Nuklearmedizin - NuclearMedicine, 58 (04), 328-330. https://doi.org/10.1055/a-0914-2486
Mit CareLit weiterarbeiten